Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
No open-market purchases or sales by Vertex Pharmaceuticals Inc insiders were filed in the last 90 days; 1,770 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $139.7B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +84 vs. previous quarter
- 1,770
- 13F valueReported value at the end of Q2 2026
- $119.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $12.0B
- +8.9% year over year
- Net income, FY2025
- $3.95B
- No comparable prior period
- Free cash flow, FY2025
- $3.19B
- No comparable prior period
- Revenue, Q3 FY2026
- $3.44B
- +11.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 4.26M
- Shares sold short
- Change
- −239.9K
- −5.3% vs. previous
- Days to cover
- 3.39
- At average daily volume
Superinvestors holding VRTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VRTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vertex Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)4:15 PM ET | Jul 2 | 5 days | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | SSale | −1.50K | $524.99 | −$787.5K | −3.2%45.3K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:08 PM ET | Jul 2 | 5 days | McKechnie DuncanEVP, Chief Commercial Officer | SSale | −1.54K | $519.00 | −$799.8K | −12.3%11.0K after | 10b5-1 |
| Jul 6, 2026 (view filing)4:13 PM ET | Jul 1 | 5 days | Liu JoyEVP and Chief Legal Officer | SSale | −828 | $502.71 | −$416.2K | −4.1%19.1K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Bozic CarmenEVP and CMO | SSale | −596 | $482.50 | −$287.6K | −3.7%15.3K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 18 | 5 days | Bozic CarmenEVP and CMO | SSale | −1.02K | $462.17 | −$471.4K | −6.0%15.9K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Bozic CarmenEVP and CMO | SSale | −4.06K | $450.00 | −$1.83M | −19.3%17.0K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 5 | 4 days | Bozic CarmenEVP and CMO | SSale | −1.75K | $450.00 | −$785.3K | −7.7%21.0K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Liu JoyEVP and Chief Legal Officer | SSale | −828 | $439.91 | −$364.2K | −4.0%20.0K after | 10b5-1 |
| Jun 2, 2026 (view filing) | May 29 | 4 days | Bozic CarmenEVP and CMO | SSale | −1.97K | $450.00 | −$888.3K | −8.0%22.8K after | 10b5-1 |
| May 19, 2026 (view filing) | May 15 | 4 days | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −33 | $453.45 | −$15.0K | −0.5%7.28K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 1,770 holdersThe largest institutional positions in Vertex Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital World Investors | 26,115,014 | $13.0B | 1.53% | +746,890+2.9% | Added |
| BlackRock, Inc. | 24,109,373 | $12.0B | 0.18% | +139,856+0.6% | Added |
| Capital Research Global Investors | 19,490,637 | $9.68B | 1.35% | −1,635,327−7.7% | Reduced |
| Vanguard Capital Management LLC | 16,580,713 | $8.24B | 0.18% | +67,903+0.4% | Added |
| State Street Corp | 11,871,459 | $5.90B | 0.17% | +141,320+1.2% | Added |
| Invesco Ltd. | 8,043,052 | $4.00B | 0.32% | +150,441+1.9% | Added |
| JPMorgan Chase & Co | 6,517,600 | $3.26B | 0.19% | −515,556−7.3% | Reduced |
| Geode Capital Management, LLC | 6,017,848 | $2.98B | 0.16% | −121,773−2.0% | Reduced |
| Vanguard Portfolio Management LLC | 4,878,987 | $2.42B | 0.11% | −266,622−5.2% | Reduced |
| Capital International Investors | 4,695,144 | $2.33B | 0.48% | −430,933−8.4% | Reduced |
Holders of 5% or more of VRTX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vertex Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Capital World Investors | 13G/A | 10.10%25.7M shares | −1.10 ppfrom 11.20% | Feb 13, 20235 filings | May 14, 2026 | SEC |
| Capital Research Global Investors | 13G/A | 8.30%21.1M shares | +1.50 ppfrom 6.80% | May 13, 20253 filings | May 14, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 7.49%19.0M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Politician trades
All politician trades in VRTX12 members of Congress reported 22 trades in Vertex Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 5, 2026 |  David J. Taylor House · OH | Sell | $1K-$15K |
| Aug 5, 2026 |  Tommy Tuberville Senate · AL | Sell (full) | $1K-$15K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $1K-$15K |
| Feb 2, 2026 | David J. Taylor House · OH | Sell | $1K-$15K |
| Jan 13, 2026 |  Julia Letlow House · LA | Buy | $1K-$15K |
House · OH · Sep 5, 2026
Sell$1K-$15K
Senate · AL · Aug 5, 2026
Sell (full)$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K
House · OH · Feb 2, 2026
Sell$1K-$15K
House · LA · Jan 13, 2026
Buy$1K-$15K